Molecular Characterization of Helodermin-Preferring VIP Receptors in SUP T₁ Lymphoma Cells: Evidence for Receptor Glycosylation

References

• Robberecht P., Waelbroeck M., De Neef P., Tastenoy M., Gourlet P., Cogniaux J., Christophe J. A new type of functional VIP receptor has an affinity for helodermin in human SUP-T1 lymphoblasts. FEBS Lett. 1988; 228: 351–355
   Google Scholar
• Vandermeers A., Gourlet P., Vandermeers-Piret M. C., Cauvin A., De Neef P., Rathé J., Svoboda M., Robberecht P., Christophe J. Chemical, immunological and biological properties of peptides like vasoactive-intestinal-peptide and peptide-histidine-isoleucinamide extracted from the venom of two lizards (Heloderma horridum and Heloderma suspectum). Eur. J. Biochem. 1987; 164: 321–327
   PubMedGoogle Scholar
• Robberecht P., De Neef P., Gourlet P., Cauvin A., Coy D. H., Christophe J. Pharmacological characterization of the novel helodermin/VIP receptor present in human SUP-T1 lymphoma cell membranes. Regul. Peptides 1989; 26: 117–126
   Google Scholar
• Bawab W., Farjaudon N., Le Meuth V., Chastre E., Rosselin G., Guilloteau P., Gespach C. Helodermin-preferring 125I-VIP binding sites during the postnatal development of the pancreas. Regul. Peptides 1989; 26: 141
   Google Scholar
• Gespach C., Chedeville A., Hurbain-Kosmath I., Housset B., Derenne J. P., Abita J. P. Adenylate cyclase activation by VIP-helodermin and histamine M2 receptors in human THP-1 monocytes/macrophages: A possible role in the regulation of superoxide anions production. Regul. Peptides 1989; 26: 158
   Google Scholar
• Luis J., Said S. I. Characterization of a VIP- and helodermin-preferring receptors on human small cell lung carcinoma (SCLC) cell lines. Regul. Peptides 1989; 26: 167
   Google Scholar
• Christophe J., Conlon T. P., Gardner J. D. Interaction of porcine vasoactive intestinal peptide with dispersed pancreatic acinar cells from the Guinea pig: binding of radioiodinated peptide. J. Biol. Chem. 1976; 251: 4629–4634
   PubMed Web of Science ®Google Scholar
• Robberecht P., Waelbroeck M., De Neef P., Camus J. C., Vandermeers A., Vandermeers-Piret M. C., Christophe J. Specific labelling by 125I-helodermin of high-affinity VIP receptors in rat liver membranes. FEBS Lett. 1984; 172: 55–58
   Google Scholar
• Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680–685
   PubMed Web of Science ®Google Scholar
• Salomon Y., Londos C., Rodbell M. A highly sensitive adenylate cyclase assay. Anal. Biochem. 1974; 58: 541–548
   PubMed Web of Science ®Google Scholar
• Robberecht P., Waelbroeck M., Camus J. C., De Neef P., Coy D. H., Christophe J. Effects of His modifications on the ability of vasoactive intestinal peptide to stimulate adenylate cyclase from rat and human tissues. Peptides 1984; 5: 877–881
   Google Scholar
• Laburthe M., Couvineau A. Molecular analysis of vasoactive intestinal peptide receptors, A comparison with receptors for VIP-related peptides. Ann. N.Y. Acad. Sci. 1988; 527: 296–313
   Google Scholar
• Dickinson K. E. J., Schachter M., Miles C. M. M., Coy D. H., Sever P. S. Characterization of vasoactive intestinal peptide (VIP) receptors in mammalian lung. Peptides 1986; 7: 791–800
   Google Scholar
• Svoboda M., Poloczek P., Winand J., Robberecht P., Christophe J. Species differences in the molecular characteristics of vasoactive-intestinal-peptide receptors in the pancreas from rat and guinea pig. Eur. J. Biochem. 1988; 174: 59–66
   Google Scholar
• Couvineau A., Laburthe M. The human vasoactive intestinal peptide receptor: molecular identification by covalent cross-linking in colonic epithelium. J. Clin. Endocrinol. Metab. 1985; 61: 50–55
   Google Scholar
• Couvineau A., Rousset M., Laburthe M. Molecular identification and structural requirement of vasoactive intestinal peptide (VIP) receptors in the human colon adenocarcinoma cell line. HT-29. Biochem. J. 1985; 231: 139–143
   Google Scholar
• Muller J. M., Luis J., Fantini J., Abadie B., Giannellini F., Marvaldi J., Pichon J. Covalent cross-linking of vasoactive intestinal peptide (VIP) to its receptor in intact colonic adenocarcinoma cells in culture (HT/29). Eur. J. Biochem. 1985; 151: 411–417
   Google Scholar
• Wood C. L., O'Dorisio M. S. Covalent cross-linking of vasoactive intestinal polypeptide to its receptors on intact human lymphoblasts. J. Biol. Chem. 1985; 260: 1243–1247
   PubMed Web of Science ®Google Scholar
• Couvineau A., Laburthe M. The rat liver vasoactive intestinal peptide binding site. Molecular characterization by covalent cross-linking and evidence for differences from the intestinal receptor. Biochem. J. 1985; 225: 473–479
   Google Scholar
• Nguyen T. D., Williams J. A., Gray G. M. Vasoactive intestinal peptide receptor on liver plasma membranes: characterization as a glycoprotein. Biochemistry 1986; 25: 361–368
   PubMed Web of Science ®Google Scholar
• El Battari A., Luis J., Martin J. M., Fantini J., Muller J. M., Marvaldi J., Pichon J. The glycoprotein nature of the vasoactive intestinal peptide binding site, Role of carbohydrates in VIP binding on HT29-D4 cells. Ann. N.Y. Acad. Sci. 1988; 527: 667–671
   Google Scholar
• Hecht F., Morgan R., Kaiser-McCaw Hecht B., Smith S. D. Common region on chromosome 14 in T-cell leukemia and lymphoma. Science 1984; 226: 1445–1447
   PubMed Web of Science ®Google Scholar
• Smith S. D., Shatsky M., Cohen P. S., Warnke R., Link M. P., Glader B. E. Monoclonal antibody and enzymatic profiles of human malignant T-lymphoid cells and derived cell lines. Cancer Res. 1984; 44: 5657–5660
   PubMed Web of Science ®Google Scholar
• Chastre E., Bawab W., Faure C., Emami S., Muller F., Boué A., Gespach C. Vasoactive intestinal peptide and its receptors in fetuses with cystic fibrosis. Am. J. Physiol. 1989; 257: G561–G569
   Google Scholar
• Gespach C., Bawab W., de Cremoux P., Calvo F. Pharmacology, molecular identification and functional characteristics of vasoactive intestinal peptide receptors in human breast cancer cells. Cancer Res. 1989; 48: 5079–5083
   Google Scholar
• König R., Ashwell G., Hanover J. A. Glycosylation of CD4, Tunicamycin inhibits surface expression. J. Biol. Chem. 1988; 263: 9502–9507
   PubMed Web of Science ®Google Scholar
• George S., Ruoho A., Mollon C. N-Glycosylation in expression and function of β-adrenergic receptors. J. Biol. Chem. 1986; 261: 16559–16564
   PubMed Web of Science ®Google Scholar
• Stiles G. Deglycosylated mammalian β2-adrenergic receptors: effect on radioligand binding and peptide mapping. Arch. Biochem. Biophys. 1985; 237: 65–71
   PubMed Web of Science ®Google Scholar
• Reed B. C., Ronnett G. V., Lane M. D. Role of glycosylation and protein synthesis in insulin receptor metabolism by 3T3-L1 mouse adipocytes. Proc. Natl. Acad. Sci. 1981; 78: 2908–2912
   PubMed Web of Science ®Google Scholar